Overview
Study to Investigate the Treatment Benefits of Probiotic Streptococcus Salivarius K12 for Mild-to-moderate COVID-19
Status:
Recruiting
Recruiting
Trial end date:
2021-12-31
2021-12-31
Target enrollment:
0
0
Participant gender:
All
All
Summary
This is a randomised, open-label and controlled clinical trial aimed to investigate the adjuvant treatment benefits of probiotic Streptococcus salivarius K12 in hospitalised mild-to-moderate patients with COVID-19 disease.Phase:
N/AAccepts Healthy Volunteers?
NoDetails
Lead Sponsor:
King Edward Medical University
Criteria
Inclusion Criteria:- Age ≥ 18 years (both sexes)
- Hospitalized Confirmed (RT-PCR) COVID-19 patients (not already in ICU)
- Patients who have signed informed consent
Exclusion Criteria:
- Patients with proven hypersensitivity or allergic reaction to the tested formula
- Patients who decline to participate in the study